Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 840-lymphoma-and-non-acute-leukemia-with-mcc
    Ask Trek AI about this page

    Lymphoma and Non-Acute Leukemia with MCC: Inpatient Reimbursement Overview

    DRG 840 addresses hospitalizations for lymphoma and non-acute leukemia with at least one Major Complication or Comorbidity and encompasses the increased clinical complexity that affects resource use. This Diagnosis-Related Group matters for inpatient reimbursement because assignments to this higher-severity category lead to higher Medicare payment weights reflecting greater expected costs.

    Customize your policy alerts

    Sign up for drg 840 policy alerts

    Get alerted when payer policies referencing 840 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 840 Overview

    DRG 840 covers inpatient admissions for patients with lymphoma and non-acute leukemia accompanied by at least one Major Complication or Comorbidity. This Diagnosis-Related Group captures higher-severity medical complexity related to hematologic malignancies, including treatment complications, organ dysfunction, or severe infection. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group typically receive higher relative weights reflecting greater resource use and cost intensity during hospitalization. Accurate clinical documentation and coding determine eligibility for this Diagnosis-Related Group and thereby influence inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials of induction and consolidation regimens for aggressive lymphoma and non-acute leukemias: randomized or single-arm trials that evaluate different chemotherapy intensity levels, sequencing with immunotherapy or targeted agents, and the role of supportive-care measures during the initial inpatient-focused treatment phase. These studies enroll adult and older adult inpatients with newly diagnosed high-grade lymphoma or non-acute leukemias who require hospitalization for cytoreductive therapy, febrile neutropenia risk management, or tumor lysis prophylaxis; they seek to define regimens that maximize remission rates while minimizing short-term life-threatening complications. Results inform inpatient resource utilization, length of stay, transfusion needs, and upfront cost-effectiveness considerations that are directly relevant to hospital billing and DRG-based reimbursement.
    • Comparative effectiveness and safety studies of inpatient management strategies for treatment-related complications: observational cohorts or pragmatic trials comparing protocols for management of neutropenic fever, tumor lysis syndrome, or severe cytopenias (for example different antimicrobial stewardship pathways, growth factor timing, or transfusion thresholds). These studies focus on hospitalized patients with lymphoma or non-acute leukemia who develop acute toxicities during therapy and aim to reduce morbidity, ICU transfers, and readmissions. Evidence from these studies guides clinical pathways, reduces variability in inpatient care, and helps payers and providers predict costs and set quality benchmarks tied to this DRG.
    • Post-discharge outcomes and care-transition research including readmission-reduction and survivorship studies: prospective observational studies and care-model interventions that track patients after inpatient stays for lymphoma or non-acute leukemia to evaluate 30- and 90-day readmission rates, outpatient care coordination, and long-term functional outcomes. These trials enroll patients discharged after induction or complication management to test discharge planning, early outpatient follow-up, and remote monitoring strategies aimed at preventing avoidable rehospitalizations. Findings are important for bundled-payment planning, risk adjustment in reimbursement models, and designing post-acute services that reduce total cost of care for this DRG.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.